Encapsulation of dexamethasone into biodegradable polymeric nanoparticles

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmaceutical Sciences

Background:

• Biodegradable nanoparticles are crucial for drug delivery.
• Poly(D,L-lactide-co-glycolide) (PLGA) is a widely used polymer for nanoparticle formulation.
• Dexamethasone (DXM) is a potent anti-inflammatory drug with therapeutic applications.

Purpose of the Study:

• To optimize the encapsulation of dexamethasone (DXM) within poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles.
• To investigate the release profile of DXM from the optimized nanoparticles.
• To understand the physical state of DXM within the nanoparticles.

Main Methods:

• Solvent evaporation technique was employed for nanoparticle preparation.
• Various parameters were screened, including solvent type, polymer type, drug loading, evaporation rate, and lipid incorporation.
• Nanoparticle characterization included size, zeta potential, differential scanning calorimetry (DSC), and X-ray diffraction (XRD).

Main Results:

• Optimized DXM encapsulation was achieved using 100 mg PLGA 75:25 in an acetone-dichloromethane mixture with 10 mg DXM.
• The optimized nanoparticles (approx. 230 nm, zeta potential -4 mV) showed complete DXM release within 4 hours at 37°C.
• DSC and XRD confirmed molecular dispersion of DXM within the nanoparticles, while unencapsulated DXM crystallized.

Conclusions:

• Feasible optimization of dexamethasone (DXM) encapsulation in PLGA nanoparticles was demonstrated.
• The developed nanoparticles offer a promising system for the controlled delivery of DXM.
• Understanding drug-polymer interactions is key for successful nanoparticle formulation.